PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33264068-8	2021	We found increased MAO-A expression in the pulmonary vasculature of PAH patients and in experimental PH induced by SuHx.	suhx	115-119	monoamine oxidase A	Homo sapiens	19-24
34508866-8	2022	During coupled respiration with complex I substrates, ST2-/- attenuated SuHx inhibition of mitochondrial respiration (genotype x treatment interaction F(1,67) = 3.3, p = 0.07, eta2 = 0.04).	suhx	72-76	interleukin 1 receptor-like 1	Mus musculus	54-57
31173066-8	2020	Consistent with these observations, we found that neutralization of CXCL12 attenuates right ventricular hypertrophy, pulmonary vascular remodelling, and decreases PA-SMC proliferation in lungs of MCT-injected rats and SuHx rats.	suhx	218-222	C-X-C motif chemokine ligand 12	Rattus norvegicus	68-74
32256050-9	2020	Additionally, PF inhibited SuHx-induced down-regulation of endothelial marker (vascular endothelial cadherin) and up-regulation of mesenchymal markers (fibronectin and vimentin) in lung, suggesting that PF could inhibit SuHx-induced endothelial-to-mesenchymal transition (EndMT) in lung.	suhx	27-31	cadherin 5	Rattus norvegicus	79-108
32256050-9	2020	Additionally, PF inhibited SuHx-induced down-regulation of endothelial marker (vascular endothelial cadherin) and up-regulation of mesenchymal markers (fibronectin and vimentin) in lung, suggesting that PF could inhibit SuHx-induced endothelial-to-mesenchymal transition (EndMT) in lung.	suhx	27-31	fibronectin 1	Rattus norvegicus	152-163
32256050-9	2020	Additionally, PF inhibited SuHx-induced down-regulation of endothelial marker (vascular endothelial cadherin) and up-regulation of mesenchymal markers (fibronectin and vimentin) in lung, suggesting that PF could inhibit SuHx-induced endothelial-to-mesenchymal transition (EndMT) in lung.	suhx	27-31	vimentin	Rattus norvegicus	168-176
32521690-9	2020	Methods: the BMPR2 expression was analyzed by Western blot analysis and immunofluorescence (IF) microscopy to determine the quantity and localization of the receptor in the lung tissue from normal control subjects and patients with hereditary or idiopathic PAH, as well as in the lungs of control rats and rats with MCT or SuHx-induced PAH.	suhx	323-327	bone morphogenetic protein receptor type 2	Homo sapiens	13-18
32108526-8	2020	SFN prevented SuHx-induced RV dysfunction and remodeling, reduced RV inflammation and fibrosis, upregulated Nrf2 expression and its downstream gene NQO1, and reduced the inflammatory mediator leucine-rich repeat and pyrin domain-containing 3 (NLRP3).	suhx	14-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	108-112
32108526-8	2020	SFN prevented SuHx-induced RV dysfunction and remodeling, reduced RV inflammation and fibrosis, upregulated Nrf2 expression and its downstream gene NQO1, and reduced the inflammatory mediator leucine-rich repeat and pyrin domain-containing 3 (NLRP3).	suhx	14-18	NAD(P)H dehydrogenase, quinone 1	Mus musculus	148-152
32108526-8	2020	SFN prevented SuHx-induced RV dysfunction and remodeling, reduced RV inflammation and fibrosis, upregulated Nrf2 expression and its downstream gene NQO1, and reduced the inflammatory mediator leucine-rich repeat and pyrin domain-containing 3 (NLRP3).	suhx	14-18	NLR family, pyrin domain containing 3	Mus musculus	243-248
32108526-11	2020	Thus, SuHx-induced RV and pulmonary dysfunction, inflammation, and fibrosis can be attenuated or prevented by SFN, supporting the rationale for further studies to investigate SFN and the role of Nrf2 and NLRP3 pathways in preclinical and clinical PAH studies.NEW & NOTEWORTHY Pulmonary arterial hypertension (PAH) in this murine model (SU5416 + hypoxia) is associated with early changes in right ventricular (RV) diastolic and systolic function.	suhx	6-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	195-199
32108526-11	2020	Thus, SuHx-induced RV and pulmonary dysfunction, inflammation, and fibrosis can be attenuated or prevented by SFN, supporting the rationale for further studies to investigate SFN and the role of Nrf2 and NLRP3 pathways in preclinical and clinical PAH studies.NEW & NOTEWORTHY Pulmonary arterial hypertension (PAH) in this murine model (SU5416 + hypoxia) is associated with early changes in right ventricular (RV) diastolic and systolic function.	suhx	6-10	NLR family, pyrin domain containing 3	Mus musculus	204-209
31173066-10	2020	Finally, we found that CXCL12 neutralization decreases vascular pericyte coverage and macrophage infiltration in lungs of both MCT-injected and SuHx rats.	suhx	144-148	C-X-C motif chemokine ligand 12	Rattus norvegicus	23-29
24684441-2	2014	We aimed to determine the role of the classical NF-kappaB pathway in severe pulmonary arterial hypertension (PAH) induced by SU5416 and chronic hypoxia (SuHx) in rats.	suhx	153-157	nuclear factor kappa B subunit 1	Homo sapiens	48-57
30354494-9	2018	In the monocrotaline and SuHx (Sugen hypoxia) rat pulmonary arterial hypertension models, increased lung 18FLT uptake was strongly associated with peripheral pulmonary vascular muscularization and the proliferation marker, Ki-67 score, together with prominent TK1 expression in remodeled vessels.	suhx	25-29	thymidine kinase 1	Rattus norvegicus	260-263
27471204-2	2016	Pulmonary arterial endothelial cell (PAEC) hyperproliferation and survival underlies the endothelial pathobiology of the disease.The indispensable involvement of Notch1 in the arterial endothelial phenotype and angiogenesis provides intriguing prospects for its involvement in the pathogenesis of PAH.We observed an increased expression of Notch1 in lungs of idiopathic PAH (IPAH) patients and hypoxia/SU5416 (SUHx) rats compared with healthy subjects.	suhx	410-414	notch receptor 1	Homo sapiens	162-168
27471204-6	2016	Furthermore, in vivo treatment with a gamma-secretase inhibitor (AMG2008827) significantly reduced the right ventricular systolic pressure and right heart hypertrophy in SUHx rats.Here, we conclude that Notch1 plays a critical role in PAH and Notch inhibitors may be a promising therapeutic option for PAH.	suhx	170-174	notch receptor 1	Rattus norvegicus	203-209
27471204-6	2016	Furthermore, in vivo treatment with a gamma-secretase inhibitor (AMG2008827) significantly reduced the right ventricular systolic pressure and right heart hypertrophy in SUHx rats.Here, we conclude that Notch1 plays a critical role in PAH and Notch inhibitors may be a promising therapeutic option for PAH.	suhx	170-174	notch receptor 1	Homo sapiens	203-208
26386116-3	2015	While these animal models resemble human PAH only with respect to vascular media remodeling, we hypothesized that SERT is likewise required for the presence of lumen-obliterating intima remodeling, a hallmark of human PAH reproduced in the Sugen hypoxia (SuHx) rat model of severe angioproliferative pulmonary hypertension.	suhx	255-259	solute carrier family 6 member 4	Homo sapiens	114-118
25713318-7	2015	OVX worsened SuHx-induced decreases in CI and SuHx-induced increases in RVH and inflammation (MCP-1 and IL-6).	suhx	13-17	mast cell protease 1-like 1	Rattus norvegicus	94-99
25713318-7	2015	OVX worsened SuHx-induced decreases in CI and SuHx-induced increases in RVH and inflammation (MCP-1 and IL-6).	suhx	13-17	interleukin 6	Rattus norvegicus	104-108
25713318-7	2015	OVX worsened SuHx-induced decreases in CI and SuHx-induced increases in RVH and inflammation (MCP-1 and IL-6).	suhx	46-50	mast cell protease 1-like 1	Rattus norvegicus	94-99
25713318-7	2015	OVX worsened SuHx-induced decreases in CI and SuHx-induced increases in RVH and inflammation (MCP-1 and IL-6).	suhx	46-50	interleukin 6	Rattus norvegicus	104-108
25713318-12	2015	RV-protective E2 effects observed in females were recapitulated in male SuHx rats treated with E2 or with pharmacological ERalpha or ERbeta agonists.	suhx	72-76	estrogen receptor 1	Rattus norvegicus	122-129
25713318-12	2015	RV-protective E2 effects observed in females were recapitulated in male SuHx rats treated with E2 or with pharmacological ERalpha or ERbeta agonists.	suhx	72-76	estrogen receptor 2	Rattus norvegicus	133-139
30636542-4	2019	In agreement with these observations, we found that the BMP9/BMP10 ligand trap ALK1ECD administered in monocrotaline or Sugen/hypoxia (SuHx) rats substantially attenuate proliferation of pulmonary vascular cells, inflammatory cell infiltration, and regresses established pulmonary hypertension in rats.	suhx	135-139	growth differentiation factor 2	Mus musculus	56-60
30636542-4	2019	In agreement with these observations, we found that the BMP9/BMP10 ligand trap ALK1ECD administered in monocrotaline or Sugen/hypoxia (SuHx) rats substantially attenuate proliferation of pulmonary vascular cells, inflammatory cell infiltration, and regresses established pulmonary hypertension in rats.	suhx	135-139	bone morphogenetic protein 10	Rattus norvegicus	61-66
29695452-4	2018	In the SU5416/hypoxia (SuHx) rat model, oral treatment with the PPARgamma agonist pioglitazone completely reverses severe PAH and vascular remodeling and prevents RV failure.	suhx	23-27	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	64-73
28935639-4	2018	To study this, sugen5416 and hypoxia (SuHx)-induced PAH was established in Cdh5-Cre/Gt(ROSA)26Sortm4(ACTB-tdTomato,EGFP)Luo/J double transgenic mice, in which GFP was stably expressed in pan-endothelial cells.	suhx	38-42	cadherin 5	Mus musculus	75-79
24684441-5	2014	Nuclear staining for NF-kappaB, an indicator of the activation of the classical NF-kappaB pathway, was detected in pulmonary arterial lesions of patients with iPAH and SuHx rats.	suhx	168-172	nuclear factor kappa B subunit 1	Homo sapiens	21-30
24684441-5	2014	Nuclear staining for NF-kappaB, an indicator of the activation of the classical NF-kappaB pathway, was detected in pulmonary arterial lesions of patients with iPAH and SuHx rats.	suhx	168-172	nuclear factor kappa B subunit 1	Homo sapiens	80-89
25006442-4	2014	Here we describe the levels of HDAC activity in the lungs and hearts of rats with pulmonary hypertension and right heart hypertrophy or failure, experimentally induced by monocrotaline (MCT), the combined exposure to the VEGF-R inhibitor SU5416 and hypoxia (SuHx), and pulmonary artery banding (PAB).	suhx	258-262	histone deacetylase 9	Homo sapiens	31-35